APP and Alzheimer disease: Both B cell-deficient mouse models of AD had reduced amounts of amyloid deposits in the brain and improved cognitive abilities (at 50–60 weeks in 3xTgAD-BKO mice and 20–35 weeks in APP/PS1-BKO mice) as compared to animals of the same background in which B cells were not knocked out.